Jesse’s Journey Becomes Defeat Duchenne Canada
New Name – Same Mission: Jesse’s Journey Becomes Defeat Duchenne Canada
Jesse’s Journey, Canada’s only national charity dedicated to ending the most common and most fatal form of muscular dystrophy has become Defeat Duchenne Canada. The London-based organization has united families, raised awareness and funded almost $15 million in research projects around the world. After more than 30 years under the banner of Jesse’s Journey, Canada’s leading fundraiser for Duchenne muscular dystrophy has partnered with its vibrant community members to choose a new name that reflects their nationwide impact.
Read the full press release from Defeat Duchenne Canada here.
About Defeat Duchenne Canada
Defeat Duchenne Canada is the country’s only national charity dedicated to ending Duchenne muscular dystrophy.
Their goal is to provide leadership in research, advocacy and support to ensure our boys can live long and active lives.
The NMD4C are excited to continue our partnership with Defeat Duchenne Canada, and are grateful to have the opportunity to work together to raise the standards of care for NMDs and access to therapies across Canada.
Check out the three-part Defeat Duchenne Canadian Conference Series addressing Duchenne Muscular Dystrophy Standards of Care in Canada, hosted in 2021 by Defeat Duchenne Canada in collaboration with MDC and the NMD4C.
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.